medwireNews: ASCO has updated its recommendations for using biomarker assays to guide adjuvant therapy decisions in people with early-stage breast cancer.
Noting that the previous version was published in 2016, the guideline authors say: “This report aims to provide more precise guidelines on how to use previously endorsed genomic tests and to provide recommendations on the use of new biomarkers to guide endocrine and chemotherapy recommendations.”
They present guidance on the appropriate use of a host of biomarker assays, including Oncotype DX, MammaPrint, Prosigna, and the immunohistochemistry 4 score, among others, to guide treatment decisions for patients with hormone receptor-positive, HER2-negative disease.
But the authors stress that “[n]one of the assays are recommended for treatment guidance in individuals with HER2-positive or triple-negative breast cancer,” and that “[t]reatment decisions should also consider disease stage, comorbidities, and patient preferences.”
To develop the guideline – published in the Journal of Clinical Oncology – a multidisciplinary panel of experts drew on 24 articles published between January 2016 and October 2021 to inform the evidence base.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group